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Mutations in PNKP Cause Recessive Ataxia
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Hereditary autosomal-recessive cerebellar ataxias are a genetically and clinically heterogeneous group of disorders. We used homozygos-
ity mapping and exome sequencing to study a cohort of nine Portuguese families who were identified during a nationwide, population-
based, systematic survey as displaying a consistent phenotype of recessive ataxia with oculomotor apraxia (AOA). The integration of data
from these analyses led to the identification of the same homozygous PNKP (polynucleotide kinase 30-phosphatase) mutation,
c.1123G>T (p.Gly375Trp), in three of the studied families. When analyzing this particular gene in the exome sequencing data from
the remaining cohort, we identified homozygous or compound-heterozygous mutations in five other families. PNKP is a dual-function
enzyme with a key role in different pathways of DNA-damage repair. Mutations in this gene have previously been associated with an
autosomal-recessive syndrome characterized by microcephaly; early-onset, intractable seizures; and developmental delay (MCSZ). The
finding of PNKPmutations associated with recessive AOA extends the phenotype associated with this gene and identifies a fourth locus
that causes AOA. These data confirm that MCSZ and some forms of ataxia share etiological features, most likely reflecting the role of
PNKP in DNA-repair mechanisms.Hereditary autosomal-recessive cerebellar ataxias (ARCAs)
are rare neurodegenerative disorders that are clinically
and genetically very heterogeneous and are characterized
by cerebellar ataxia that is frequently associated with pe-
ripheral sensorimotor neuropathy. Ataxia with oculomotor
apraxia (AOA) is a subgroup involving cerebellar ataxia,
sensorimotor axonal neuropathy, oculomotor apraxia,
and extrapyramidal features. Chromosomal instability,
immunodeficiency, and sensitivity to ionizing radiations,
all usually observed in persons with ataxia telangiectasia
(AT) and AT-like disorders, are absent in individuals with
AOA.1 Early-onset recessive ataxia (AOA1 or EAOH [MIM
208920]) is a progressive syndrome associated with hypoal-
buminemia and elevated levels of cholesterol and is caused
by mutations in APTX (aprataxin).1–3 Autosomal-recessive
spinocerebellar ataxia 1 (AOA2 or SCAR1 [MIM 606002]),
a progressive ataxia,4 occurring later than AOA1, is charac-
terized by increased alpha-fetoprotein levels and is caused
by mutations in SETX (senataxin).5 A third gene, PIK3R5
(phosphoinositide-3-kinase, regulatory subunit 5; AOA3
[MIM 615217]), has been identified in a consanguineous
Saudi Arabian family whose affectedmembers have clinical
features similar to those of individuals with AOA2.6
Next-generation sequencing technologies have been
remarkably useful for the identification of novel genes
causing Mendelian diseases. At the same time, these
recently developed technologies have allowed the expan-
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with a large-spectrum phenotype or very different pheno-
types can be explained by several factors, one being the
pleiotropism associated with many genes.7
We used exome sequencing and homozygosity mapping
to study a series of nine Portuguese families affected by
early-onset recessive AOA. These families were identified
during a nationwide, population-based, systematic survey
of hereditary ataxias and spastic paraplegias. Performed
in Portugal from 1994 to 2004, this survey used multiple
sources of information to identify affected persons in the
community and health-care settings. Detailed methods
of the survey are described elsewhere.8 All individuals
studied here presented established clinical criteria for
AOA,1 and samples were collected after receipt of written
informed consent from participants. This study used
only de-identified, previously collected DNA samples that
were stored at the authorized Center for Predictive and Pre-
ventive Genetics, Institute for Molecular and Cell Biology
biobank and database.
After previous exclusion of mutations in the genes
known to be directly associated with this phenotype
(APTX, SETX, and PIK3R5), we performed whole-genome
genotyping in ten individuals from seven families
(nine affected and one unaffected). We used Illumina
OmniExpress Beadchips, which assay over 700,000
markers, as per the manufacturer’s instructions. We used
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control, which led to the exclusion of three samples (two
from family 2 and one from family 6) from further analysis
involving whole-genome genotyping data. Runs of homo-
zygosity (ROH) were identified with PLINK v.1.079 on the
basis of having a size greater than 1.5 Mb and a minimum
of 50 SNPs per region. We scanned the genome for regions
of homozygosity by using a sliding window of 50 SNPs
and allowing at most two missing genotypes and one
heterozygote call per ROH. We focused the initial homozy-
gosity mapping on pedigrees with reported consanguinity
(families 5 and 7). The only homozygous region, a
region >1.5 Mb and shared by all affected individuals, was
on chromosome 19 (49,506,390–51,400,356) (Figure S1).
Upon analysis of the other families, we found that the pro-
band of family 8 also shared a large homozygous tract over-
lapping this region (chr19: 49,425,838–53,225,722).
We performed exome sequencing in 16 individuals from
eight families (12 affected and four unaffected). For this
analysis, we prepared genomic DNA according to Illumi-
na’s TruSeq Sample Preparation v.3 and performed the
exome capture with Illumina’s TruSeq Exome Enrichment
according to the manufacturer’s instructions. Sequencing
was performed on an Illumina HiSeq2500 with 100-bp
paired-end reads. Following quality control procedures,
samples yielded between 10.1 and 12.7 Gb of high-quality,
aligned data. This amount of data was the result of mean
target coverage between 66.393 and 88.53, 93.5%–
94.6% of targets’ being covered at greater than or equal
to 103, and less than 0.2% of targets’ not being covered
even once. We performed sequence alignment and variant
calling against the reference human genome (UCSC
Human Genome Browser hg19) by using the Burrows-
Wheeler Aligner10 and the Genome Analysis Toolkit.11,12
Prior to variant calling, PCR duplicates were removed
with the Picard software. On the basis of the hypothesis
that the mutation was rare, we excluded all common
SNPs (MAF > 5%) identified in dbSNP v.137 and in our
in-house database of sequencing data for other diseases
(n > 2,000). Given the apparent autosomal-recessive
mode of inheritance in the three families (families 5, 7,
and 8) and the fact that two parental pairs were consan-
guineous, we focused on homozygous variants located
in the shared ROH. One PNKP mutation, c.1123G>T
(p.Gly375Trp; RefSeq accession number NM_007254.3),
was present in homozygosis in all affected individuals
and absent in all unaffected ones. Expanding this analysis
to the other studied families, we found the same mutation
in homozygosis in family 2; probands in families 1, 3, 4,
and 6 were compound heterozygotes for different muta-
tions in the same gene. The proband in family 6 was tested
by Sanger sequencing, and no causative mutations were
found in this gene in family 9. We also used Sanger
sequencing to confirm all mutations identified by exome
sequencing, establish compound heterozygosity, and
verify intrafamilial segregation. We performed PCR ampli-
fications and purified the resulting products with ExoSAP-
IT (USB), then performed direct Sanger sequencing of bothThe Amestrands with BigDye Terminator v.3.1 chemistry v.3.1
(Applied Biosystems) and an ABI 3730XL Genetic Analyzer
(Applied Biosystems). Sequencing traces were analyzed
with Sequencher software v.4.2 (Gene Codes).
Themain clinical features of the 11AOA-affected persons
(four males and seven females) who were found to have
PNKP mutations are presented in Table 1. All of them
were either homozygotes or compound heterozygotes for
PNKPmutations (Table 2 and Figure 1). Age at onset ranged
from 1 to 9 years; the mean was 4.35 2.3 years. Most indi-
viduals exhibited dystonia as their first symptom; this was
so prominent that many of these individuals underwent
diagnostic procedures for extrapyramidal disorders. In all
cases, dystonia spontaneously attenuated during the course
of the disease. The second most common symptom was
ataxia, followed by oculomotor apraxia. All individuals
had signs of polyneuropathy with early, generalized are-
flexia. Distal-muscle wasting and weakness led to tetraple-
gia and short atrophic hands and feet. Loss of the ability
towalk occurred 7–21 years after disease onset, andmost in-
dividuals were wheelchair bound by adolescence. Cogni-
tive impairment was present in seven persons, two of
whom were severely demented. Alpha-fetoprotein, albu-
min, and cholesterol levels were highly variable in this
cohort; alpha-fetoprotein levels were increased in five indi-
viduals, albumin was decreased in six, and cholesterol was
elevated in five cases, all of which was determined at later
stages of disease progression. In all 11 individuals, brain
MRIs revealed cerebellar atrophy.
Mutations in PNKP were originally found to cause
early infantile epileptic encephalopathy-10 (EIEE10 [MIM
613402]), characterized by microcephaly, seizures, and
developmental delay.13 More recently, this gene was
associated with cerebellar atrophy in two Dutch siblings
who had progressive debilitating polyneuropathy, micro-
cephaly, severe intellectual disability, and mild epilepsy.14
No ocular signs were described in those Dutch cases. None
of the individuals we studied had microcephaly or epi-
lepsy; cognitive impairment was observed in most but
not all individuals (although it progressed to severe de-
mentia in two cases).
These families were identified through a population-
based nationwide survey for hereditary ataxias, to the best
of our knowledge the largest ever performed. We can thus
conclude that AOA4 is the most frequent form of AOA in
the Portuguese population (it affects nearly 40%of the fam-
ilies identified) and the most frequent recessive ataxia in
this population, after Freidreich ataxia.8 Mean age at onset
(4.3 years) for individuals with AOA4 is closer to that of in-
dividuals with AOA1 (6.95 4.7 years) than to that of those
withAOA2 (14.653.4), although it is lower than both.16,17
Clinical presentation, with marked extrapyramidal mani-
festations and its rapid progression, also more closely re-
sembles that of AOA1 than that of AOA2. Additionally, in
individuals with AOA4, albumin may be low or normal
and cholesterol levels are normal or high, a similar situation
to what is seen in individuals with AOA1 after some yearsrican Journal of Human Genetics 96, 474–479, March 5, 2015 475
Table 1. Clinical, Biochemical, and Imaging Features of the Individuals Carrying PNKP Mutations
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6 Family 7 Family 8
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11
Consanguinity  yes   yes yes yes 
Gender male female female female male female female female male female male
Age at onset (years) 5 9 6 3 1 3 4 4 7 2 3
First sign dystonia dystonia dystonia ataxia dystonia ataxia ataxia OMA OMA dystonia dystonia
More prominent sign neurop. neurop. neurop. neurop. neurop. neurop. neurop. neurop. neurop. neurop. neurop.
OMA þþþ þþþ þ þþ þ þ þþ þþþ þþþ þþþ þþþ
Age in wheelchair (years) 18 22 18 20 NA 15 25 15 14 20 15
Dystonia þ þ þ þ þþ þ    þþ þþ
Cognitive impairment þ þ þþ þ NA    þ þþ þ
Motor deficit þþþ þþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ
Decreased vibration sense þþ þ NA þþ NA þþ þþþ þþ þþ NA þþ
Pyramidal signs   þ       þ 
Obesity   þ þ   þ   þþ 
MRI findings CA CA CA CA CA CA CA CA CA CA CA
Other features BSA BSA dem. NA NA NA NA NA NA dem. BSA
a-fetoprotein levels 1.5 N 1.5 N 1.5 N N N 1.5 N 4 N N N N N
Albumin levels N N Y Y Y Y N NA NA Y Y
Cholesterol levels N N N [ [ N [ NA NA [ [
Abbreviations and symbols are as follows: P1–P11, individuals 1–11, respectively;þ, present;þþ,moderate;þþþ, severe;, absent;[, increased level;Y, decreased
level; N, normal level; NA, not available; CA, cerebellar atrophy; BSA, brainstem atrophy; OMA, oculomotor apraxia; neurop., neuropathy; dem., dementia.of disorder progression. On the other hand, a-fetoprotein
was elevated in some individuals with AOA4, which seems
to always be the case in those with AOA2.Table 2. PNKPMutations that CausedAOA in AffectedMembers of
the Eight Portuguese Families in Whom Mutations Were Found
Family cDNA (RefSeq NM_007254.3)
Protein (RefSeq
NP_009185.2)
1 c.[1123G>T];[1253_1269dupGG
GTCGCCATCGACAAC]
p.[(Gly375Trp)];
[(Thr424Glyfs*49)]
2 c.[1123G>T];[1123G>T] p.[(Gly375Trp)];
[(Gly375Trp)]
3 c.[1221_1223del];[1549_1550ins
TGTACTGC]
p.[(Thr408del)];
[(Gln517Leufs*24)]
4 c.[1221_1223del];
[1315_1329delinsGGGT]
p.[(Thr408del)];
[(Arg439Glyfs*51)]a
5 c.[1123G>T];[1123G>T] p.[(Gly375Trp)];
[(Gly375Trp)]
6 c.[1123G>T(;)1322_1323insAGCCG] p.[(Gly375Trp(;)
Gly442Alafs*27)]
7 c.[1123G>T];[(1123G>T)] p.[(Gly375Trp)];
[(Gly375Trp)]
8 c.[1123G>T];[1123G>T] p.[(Gly375Trp)];
[(Gly375Trp)]
aOne of the allelic mutations in F4 is formed by a complex allele that was
initially not properly identified. Figure S3 shows the detailed view of the align-
ment at that position, clearly displaying the complex allele.
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tions in PNKP do not seem to relate to either the type or
the location of the mutation (Figure 1). PNKP is a modular
protein with three domains: an amino-terminal fork-head-
associated (FHA) domain, which mediates interactions
with the scaffold proteins XRCC1 and XRCC4; a
DNA phosphatase domain; and a DNA kinase domain.18
The same homozygous variant, p.Thr424Glyfs*49
(c.1253_1269dup), located in the kinase domain of the
protein, has been found in individuals with progressive
cerebellar atrophy and in individuals with MCSZ (an auto-
somal-recessive syndrome characterized by microcephaly,
early onset, intractable seizures, and developmental
delay).13,14 We have now identified this same variant in
compound heterozygosity with p.Gly375Trp in family 1.
Missense substitutions in the FHA and phosphatase do-
mains of the protein have only been associated with devel-
opmental syndromes. In most affected individuals, MCSZ
was found to be caused by the p.Glu326Lys (c.1123G>T)
variant in homozygosity.13 In the present study, variants
found to be associated with AOA were all located in, or
adjacent to, the kinase region of the protein. The position
of the most frequent variant, p.Gly375Trp, in this cohort is
highly conserved across species (Figure S2) and is located in
a potential ATP nucleotide-binding domain (amino acids
372–379) within the kinase region. Additionally, several
in-silico-prediction software programs rate this variant as, 2015
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Figure 1. Pedigrees of the Portuguese Families In which AOA-Affected Members Had PNKP Mutations and Protein Representation
with the Location of the Variants Found to Be Associated with Different Phenotypes
Black symbols represent individuals affected by AOA. An arrow indicates the index individual in each family. Mutation segregation with
disease is indicated underneath each symbol; all unaffected family members carry either a single variant (wt/mut) or no variants (wt/wt),
and all affected individuals harbor mutations in homozygosity or compound heterozygosity. In the lower panel, PNKP (RefSeq
NP_009185.2) is represented with the depicted regions as predicted by UniProtKB (Q96T60). Variants found in this study are represented
in black and are all located in or adjacent to the kinase region of the protein. Variants previously identified in individuals with MCSZ are
represented in gray. An additional 17-bp intron 15 deletion was reported in one family, which is not represented here.13 The variant
p.Thr424Glyfs*49 (in orange) has been previously associated with MSCZ13 and with progressive cerebellar atrophy and polyneurop-
athy.14 The same change was identified in compound heterozygosity with p.Gly375Trp in family 1. Targeted resequencing has also iden-
tified the p.Pro20Ser (c.58G>A) variant in an individual with epileptic encephalopathy;15 this variant was considered to be pathogenic
in the homozygous state but had previously been identified in the Exome Variant Server (overall MAF of 0.9%) and dbSNP databases and
classified as benign in ClinVar.deleterious (SIFT score ¼ 0; PolyPhen score ¼ 0.999;
CADD_phred ¼ 18.51).19
A functional assessment of the impact of MCSZ-associ-
ated PNKP mutations showed that the studied variants
reduced the cellular stability and the level of PNKP;
some ablated cellular DNA 50 kinase activity, and all stud-
ied variants reduced cellular 30 phosphatase activity.20 The
structural unit of the wild-type protein is stabilized by
the anchoring of the kinase domain to the phosphatase
domain via interactions between the five C-terminal resi-The Amedues, Q517–G521, and the interdomain linker and phos-
phatase domain.18,20 The deletion found in family 3,
although adjacent to the kinase region of the protein,
probably affects these interactions and thereby has con-
sequences for protein conformation and function. It is
possible that the different phenotypes associated with
the different mutations result from defects in the
phosphatase or kinase activities of the protein or from
conformational protein alterations that lead to deficient
protein-protein interactions or substract recognition. Itrican Journal of Human Genetics 96, 474–479, March 5, 2015 477
is also plausible that the different phenotypes are the
result of an additional genetic-variation load.21 PNKP
has important roles in multiple pathways involved
in DNA-damage repair, including single-strand breaks
(SSBs) and double-strand breaks (DSB).14,21,22 The cellular
response to these breaks involves a complex signaling
network and the key activator of this network is the
serine/threonine protein kinase ATM (AT mutated), which
has been shown to target PNKP.23,24 Mutations in ATM are
known to cause AT, another autosomal-recessive ataxia.
Mutations in other ataxia-related genes, such as TDP1 (ty-
rosyl-DNA phosphodiesterase-1, associated with spinocer-
ebellar ataxia with axonal neuropathy-1 (SCAN1) [MIM
607250]) and APTX, also result in defects in SSB repair.
In this way, the molecular involvement of PNKP in these
different pathways, and the possible compensation by
related proteins, might also contribute to the phenotypic
differences associated with mutations in this gene.22 A
STRING analysis supported this possibility, showing that
PNKP interacts with proteins involved in neurodegenera-
tive diseases and microcephaly syndromes.14 The pheno-
types associated with PNKP mutations could also be in-
fluenced by gene-environment interactions. It has been
recently demonstrated that physiologically and environ-
mentally relevant doses of cadmium and copper can
inhibit both the phosphatase and kinase activities of
PNKP.25
In this study, we identified homozygous or compound-
heterozygous PNKP mutations in eight of the nine Portu-
guese families we studied (with a total of 11 affected indi-
viduals), suggesting that, in Portugal, mutations in PNKP
are the most frequent cause of AOA. However, additional
studies are needed to determine whether this is also the
case in other populations. Our results also extend the
phenotype associated with mutations in this gene. Future
studies clarifying PNKP regulation and interaction with
other repair enzymes might help explain this phenotypic
variability.Supplemental Data
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